沙利度胺联合化疗治疗晚期肺癌血清VEGF和IL-6水平分析

目的：：分析沙利度胺联合化疗治疗晚期肺癌前后患者血清VEGF和IL-6水平的变化。方法：60例肺癌患者随机分为治疗组和对照组，每组30例。对照组患者使用GP方案治疗，治疗组患者应用GP方案+沙利度胺，治疗2个周期后评价疗效，并检测患者治疗前后血清血管内皮生长因子(VEGF)和白介素-6(IL-6)水平。结果：两组治疗有效率比较差异无统计学意义(P＞0.05)。治疗组治疗有效者治疗后血清VEGF水平明显低于治疗前(P＜0.05)；对照组治疗有效者治疗前后血清VEGF水平比较差异无统计学意义(P＞0.05)。两组治疗有效者治疗后血清IL-6水平均明显低于治疗前(P＜0.05)。两组治疗无效者治疗后血清VEGF和IL-6水平均明显高于治疗前(P＜0.05)。结论：晚期肺癌患者治疗前后血清VEGF和IL-6的水平变化可作为肺癌患者疗效预测的参考指标。

ANALYSIS OF VEGF AND IL-6 LEVEL IN SERUM OF ADVANCED LUNG CANCER PATIENTS TREATED WITH THALIDOMIDE COMBINED CHEMOTHERAPY

[ABSTRACT]Objective:To analyze the changes of VEGF and IL-6 level in serum of advanced lung cancer patients treated with thalidomide combined chemotherapy.Methods:60 cases lung cancer patients were randomly divided into treatment group and control group with 30 patients in each group. The patients in control group were treated with GP chemotherapy regimens, while the patients in treatment group were treated with GP chemotherapy regimens combined thalidomide. The curative effects were evaluated after 2 treatment cycles. And the vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) level in serum were detected respectively before and after treatment.Results:There had no statistical signiifcance about efifciency of clinical treatment between treatment group and control group (P>0.05). After treatment, the VEGF level in serum of response patients in treatment group was obviously lower than that before treatment (P<0.05). There had no statistical signiifcance about VEGF level of response patients in control group before and after treatment (P>0.05). After treatment, the IL-6 level in serum of response patients in 2 groups were all obviously lower than that before treatment (P<0.05). The VEGF and IL-6 level in serum of negative patients after treatment in 2 groups were all signiifcantly higher than that before treatment (P<0.05). Conclusions:Serum level of VEGF and IL-6 may provide predictive value for clinical effects of advanced lung cancer patients.